EDDIE GRAY - Corporate Board Profile

DYNAVAX TECHNOLOGIES CORP

Filing Date	Source Excerpt
2014-04-28	Eddie Gray 54 Chief Executive Officer ("CEO") and Director ... Mr. Gray joined Dynavax as CEO and was appointed to our Board in May 2013 ... The following table shows for the fiscal year ended December 31, 2013, certain information with respect to the compensation of all non-employee directors of the Company: (Eddie Gray is not listed in the director compensation table, indicating no director compensation)
2015-04-21	Eddie Gray 55 Chief Executive Officer ("CEO") and Director ... Mr. Gray joined Dynavax as Chief Executive Officer and was appointed to our Board in May 2013. ... Our Board believes that Mr. Gray's more than 30 years of pharmaceutical industry experience ... enables him to provide commercial and strategic leadership to the Company.
2016-04-22	Eddie Gray 57 Chief Executive Officer ("CEO") and Director ... By virtue of his employment with the Company, Eddie Gray, our Chief Executive Officer is not an independent director.
2017-04-21	Eddie Gray 58 Chief Executive Officer ("CEO") and Director ... By virtue of his employment with the Company, Eddie Gray, our Chief Executive Officer is not an independent director ... The following table shows for the fiscal year ended December 31, 2016, certain information with respect to the compensation of all non-employee directors of the Company: (Eddie Gray is not listed, indicating no non-employee director compensation).
2017-07-10	Eddie Gray, Chief Executive Officer
2018-04-20	Eddie Gray 59 Chief Executive Officer ("CEO") and Director ... By virtue of his employment with the Company, Eddie Gray, our Chief Executive Officer is not an independent director.
2019-04-22	Our Board presently has eight members. There are three directors in the class whose term of office expires in 2019: Dennis A. Carson, M.D., Eddie Gray, and Laura Brege, each of whom is a nominee for director and currently a director of the Company. Dr. Carson, Mr. Gray and Ms. Brege were previously elected by the stockholders in 2016. If each nominee is elected at the Annual Meeting, each of these nominees will serve until the 2022 Annual Meeting and until his or her successor is elected and has qualified, or, if sooner, until the director's death, resignation or removal. We have a policy encouraging our directors' attendance at our annual meetings. There were six directors in attendance at our 2018 Annual Meeting. Directors are elected by a plurality of the votes of the holders of shares present in person or represented by proxy and entitled to vote on the election of directors. The three nominees receiving the highest number of affirmative votes will be elected. Shares represented by executed proxies will be voted, if authority to do so is not withheld, for the election of the nominees named below. Although the election of directors at the Annual Meeting is uncontested and directors are elected by a plurality of votes cast, and we therefore anticipate that each of the named nominees for director will be elected at the Annual Meeting, under our Corporate Governance Guidelines, any nominee for director is required to submit an offer of resignation for consideration by the Nominating and Corporate Governance Committee if such nominee for director (in an uncontested election) receives a greater number of "Withhold" votes than "For" votes. In such case, the Nominating and Corporate Governance Committee will then consider all of the relevant facts and circumstances and recommend to the Board the action to be taken with respect to such offer of resignation. For more information on this policy see the section entitled "Corporate Governance." If any nominee becomes unavailable for election as a result of an unexpected occurrence, your shares will be voted for the election of a substitute nominee proposed by our Board. Each person nominated for election has agreed to serve if elected. Our Board has no reason to believe that any nominee will be unable to serve.